image
Healthcare - Biotechnology - NASDAQ - US
$ 8.16
-8.36 %
$ 310 M
Market Cap
4.96
P/E
CASH FLOW STATEMENT
-41.6 M OPERATING CASH FLOW
-29.73%
-27.8 M INVESTING CASH FLOW
79.91%
103 M FINANCING CASH FLOW
389.44%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Entrada Therapeutics, Inc.
image
150m150m100m100m50m50m00(50m)(50m)(100m)(100m)202020202021202120222022202320232024202420252025
Net Income 65.6 M
Depreciation & Amortization 3.77 M
Capital Expenditures -3.16 M
Stock-Based Compensation 17.9 M
Change in Working Capital -119 M
Others -130 M
Free Cash Flow -44.7 M

Cash Flow

Millions
Dec-2024 Dec-2023 Dec-2022 Dec-2021 Dec-2020 Dec-2019
OPERATING CASH FLOW
Net Income 65.6 (6.7) (94.6) (51.2) (26.5) (5.1)
Depreciation & Amortization 3.8 2.8 1.9 1.1 0.3 0.1
Deferred Income Tax 0 0 0 0 0 0
Stock Based Compensation 17.9 13.1 9.9 2.5 0.3 0.3
Other Operating Activities (10.0) (5.8) 0.2 74 K 20 K (6.3)
Change in Working Capital (118.9) 136.3 (11.1) (3.4) 0.3 0.2
Cash From Operations (41.6) 139.8 (93.8) (50.9) (25.6) (10.8)
INVESTING CASH FLOW
Capital Expenditures (3.2) (5.6) (2.9) (4.6) (2.3) (0.6)
Other Items (24.6) (132.8) (145.8) 0 7 K 0
Cash From Investing Activities (27.8) (138.4) (148.7) (4.6) (2.3) (0.6)
FINANCING CASH FLOW
Common Stock Repurchased 0 0 0.3 0 0 0
Total Debt Repaid 0 0 0 0 0 0
Dividends Paid 0 0 0 0 0 0
Other Financing Activities 3.4 1.6 0.5 116.8 50.1 38 K
Cash From Financing Activities 103.0 21.0 0.5 307.5 50.1 38 K
CHANGE IN CASH
Net Change In Cash 33.6 22.4 (242.0) 252.0 22.2 (11.4)
FREE CASH FLOW
Free Cash Flow (44.7) 134.2 (96.7) (55.4) (27.9) (11.4)